A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasm
Interventions: DRUG: PF-05212384 (gedatolisib)|DRUG: Docetaxel|DRUG: Cisplatin|DRUG: Dacomitinib
Sponsor: Pfizer